Uback rankings
How the AI ranks →| Ranking | Tier | Rank | Edition | Next update |
|---|---|---|---|---|
| AI drug discovery · worldwide | Top 13 | #1 | Edition 0 (beta) · Sep 2026 | 21 Nov 2026 |
Estimated valuation
AI · AI drug discovery ranking (worldwide)- Anchor
- Last known equity round: Series C · USD 400M · Jul 2026
- Published valuation
- USD 3.8bn · Jul 2026
An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method
Funding history
| Date | Round | Amount | Type | Investors | Source |
|---|---|---|---|---|---|
| Jul 2026 | Series C | USD 400M | Equity | Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension | finance.yahoo.com |
Rounds as cited by Uback’s rankings and their sources. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.
Independent analyses
By industry professionals & analystsIndustry professionals and financial analysts can publish their own analysis of Chai Discovery as a PDF, on one of three angles only:
Analyses are the opinion of their authors, not of Uback. They are checked before publication and never change the rank.
Comparable companies in ai drug discovery
Full ai drug discovery ranking →Investors in Chai Discovery: Index Ventures · Kleiner Perkins · Sequoia Capital · Dimension
Sources. finance.yahoo.com · endpoints.news
Last updated: Sep 2026Report an error
Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.